Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 12, 2007. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details minor acquisitions of Ordinary shares by specific individuals resulting from the reinvestment of dividends paid on October 11, 2007. The transactions occurred at a price of GBP 13.03 per share through the Company's ShareReward Plan. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider shareholdings under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investors to Verify
- The dividend reinvestment price was GBP 13.03 per Ordinary share.
- Transactions were executed on October 11, 2007, and notified on October 12, 2007.
- Acquisitions were made by Mr. J S Heslop, Mr. R Bondy, Mr. D Learmouth, Dr. D Pulman, Mr. C Viehbacher, and Mr. A P Witty.
- The number of shares acquired ranged from 3 to 13 per individual.